BeOne Medicines Ltd. (NASDAQ: ONC; previously BeiGene through October 2024) FY2025 revenue ~$5.3-5.8B (+50-60%) with adj. EPS ~$1.40-1.85 reflecting continued Tevimbra (tislelizumab; PD-1 inhibitor) ~$1.5-2B aggregate global revenue (~$1B+ China + ~$0.5-1B post-2024 US + EU + selected various global launch) plus continued Brukinsa (zanubrutinib; BTK inhibitor) ~$3.0-3.4B aggregate global revenue (~$2-2.4B+ US + EU + selected various global) plus selected post-October 2024 BeiGene → BeOne Medicines rebranding + selected continued post-2024 NASDAQ + Hong Kong + Shanghai Stock Exchange triple listing under continued co-founder + Chairman + CEO John Oyler (~14-year tenure since 2010 founding). Global biopharmaceutical company focused on oncology with operations across drug development + commercialization + selected various manufacturing in US + China + EU + selected various. Founded 2010 as BeiGene Ltd. in Beijing China by John Oyler + Xiaodong Wang (Nobel laureate) (~14-year heritage); selected post-2016 NASDAQ IPO (~$182M raised); selected post-2018 Hong Kong Stock Exchange listing IPO (~$903M raised); selected post-2021 Shanghai Stock Exchange STAR Market listing IPO (~$3.5B raised); selected post-November 2019 Brukinsa first FDA approval; selected post-March 2024 Tevimbra first FDA approval; selected post-October 2024 BeiGene → BeOne Medicines rebranding + ticker change BGNE → ONC. Headquartered in Cambridge Massachusetts US (selected post-October 2024 US HQ relocation; selected continued China + Switzerland operating sites); ~10,000+ employees globally with ~$5.3-5.8B revenue. Single primary product franchise structure: Brukinsa ~$3.0-3.4B + Tevimbra ~$1.5-2B + selected various oncology + R&D collaboration ~$0.8-1B. Brukinsa franchise leadership: ~$3.0-3.4B aggregate global revenue FY2025 (+30-40% YoY); leading BTK inhibitor globally; approved indications CLL + MCL + WM + MZL + selected various B-cell malignancies; ~50%+ aggregate US BTK new patient share; ~$5-7B+ peak sales potential. Tevimbra global launch: ~$1.5-2B aggregate global revenue FY2025; March 2024 first US FDA approval for ESCC; selected post-2024 EU EMA approval expansion; ~10+ active Tevimbra global pivotal trials covering lung + gastric + esophageal + selected various; ~$2-4B+ peak sales potential. BeiGene → BeOne Medicines rebranding: post-October 2024 brand transition + HQ relocation to Cambridge Massachusetts + selected continued China commercial + R&D + manufacturing operations + selected post-2024 China oncology pivot. Co-founder + Chairman + CEO John Oyler since 2010 founding (~14-year tenure); CFO Aaron Rosenberg. Capital structure: ~$2.5-3B aggregate cash + investments; no dividend; no buybacks (capital priority on growth + R&D); ~$1.5-2B annual R&D spend; investment-grade B2/B credit rating. FY2026 thesis: Brukinsa global franchise leadership + Tevimbra global launch + post-October 2024 BeOne Medicines rebranding + FCF positive trajectory + selected post-2024 China oncology pivot. Risks: Brukinsa Imbruvica + Calquence + Jaypirca BTK competition, Tevimbra Keytruda + Opdivo PD-1 competition, China oncology pivot execution, R&D pipeline failures, USD/CNY currency volatility.

[ONC] BeOne Medicines Thesis 2026: Tevimbra Global Launch Tests China Oncology Pivot

Key Takeaways

BeOne Medicines Ltd. (NASDAQ: ONC) FY2025 revenue ~$5.3-5.8B (+50-60% YoY) with adj. EPS ~$1.40-1.85 reflecting continued Tevimbra (tislelizumab; PD-1 inhibitor) ~~$1.5-2B aggregate global revenue (~~$1B+ China + ~$0.5-1B post-2024 US + EU + selected various global launch) plus continued Brukinsa (zanubrutinib; BTK inhibitor) ~~$3.0-3.4B aggregate global revenue (~~$2-2.4B+ US + EU + selected various global) plus selected post-October 2024 BeiGene → BeOne Medicines rebranding + selected continued post-2024 NASDAQ + Hong Kong + Shanghai Stock Exchange triple listing under continued co-founder + Chairman + CEO John Oyler (~14-year tenure since 2010 founding; ex-Susaris Medical + ex-Genta Inc + ~30+-year industry career; selected longest-tenured BeOne Medicines founder-CEO).
Brukinsa (zanubrutinib) global franchise leadership: ~$3.0-3.4B aggregate global revenue FY2025 (+30-40% YoY); selected leading BTK inhibitor globally (selected major competitor Imbruvica/Calquence/Jaypirca); selected ~50%+ aggregate US BTK new patient share; selected continued post-2024 EU + Japan + selected various global expansion; selected ~$5-7B+ peak sales potential.
Tevimbra (tislelizumab) global launch: ~$1.5-2B aggregate global revenue FY2025; selected post-2024 US FDA approval (March 2024 first US approval for esophageal squamous cell carcinoma) + selected post-2024 EU EMA approval expansion; selected continued post-2024 ~10+ active Tevimbra global pivotal trials covering selected various lung + gastric + esophageal + selected various indications; selected ~$2-4B+ peak sales potential.
Capital structure: selected ~$2.5-3B aggregate cash + investments; no dividend; no buybacks (capital priority on growth + R&D investment); selected ~$1.5-2B annual R&D spend supporting selected major Brukinsa + Tevimbra + selected various pipeline; investment-grade B2/B credit rating; selected post-October 2024 BeiGene → BeOne Medicines rebranding reflecting selected post-2024 China oncology pivot strategy + selected various global expansion focus.

Company Background

BeOne Medicines Ltd. (NASDAQ: ONC; previously BeiGene through October 2024) is a global biopharmaceutical company focused on oncology with FY2025 revenue ~$5.3-5.8B (+50-60% YoY) and adj. EPS ~$1.40-1.85 reflecting continued Tevimbra global launch + Brukinsa global franchise leadership + selected post-October 2024 BeiGene → BeOne Medicines rebranding. The company employs ~10,000+ globally with operations across drug development + commercialization + selected various manufacturing in US + China + EU + selected various.

Founded 2010 as BeiGene Ltd. in Beijing China by John Oyler + Xiaodong Wang (Nobel laureate associated National Institute of Biological Sciences) (~~14-year heritage); selected post-2016 NASDAQ IPO (~~$182M raised); selected post-2018 Hong Kong Stock Exchange listing IPO (~~$903M raised); selected post-2021 Shanghai Stock Exchange STAR Market listing IPO (~~$3.5B raised); selected post-November 2019 Brukinsa (zanubrutinib) first FDA approval for mantle cell lymphoma; selected post-March 2024 Tevimbra (tislelizumab) first FDA approval for esophageal squamous cell carcinoma; selected post-October 2024 BeiGene → BeOne Medicines rebranding (selected post-2024 strategic positioning for selected various global expansion + selected post-2024 China oncology pivot); selected post-October 2024 ticker change from BGNE → ONC.

Headquartered in Cambridge Massachusetts US (selected post-October 2024 BeOne Medicines US HQ relocation from prior Beijing China headquarters; selected continued China + Switzerland operating sites); ~10,000+ employees globally with ~$5.3-5.8B revenue. Single primary product franchise structure: Brukinsa (zanubrutinib; BTK inhibitor) ~$3.0-3.4B aggregate global revenue + Tevimbra (tislelizumab; PD-1 inhibitor) ~$1.5-2B aggregate global revenue + selected various other oncology products (XGEVA + Ranmark + selected various) ~$0.8-1B + selected various R&D collaboration revenue. Geographic mix: US ~45-50% revenue + Europe ~20% + China ~25-30% + selected various international ~5-10%.

Co-founder + Chairman + CEO John Oyler since 2010 founding (~14-year tenure as founder-CEO; selected longest-tenured BeOne Medicines founder-CEO continuing); Oyler ex-Susaris Medical + ex-Genta Inc + ~30+-year industry career; selected continued strategic priorities include Brukinsa + Tevimbra global expansion + selected post-October 2024 BeOne Medicines rebranding execution + selected post-2024 China oncology pivot. CFO Aaron Rosenberg (since post-2023; ex-various pharma + biotech roles + ~20-year industry career).

Brukinsa (Zanubrutinib) Global Franchise Leadership

BeOne Medicines Brukinsa franchise represents selected primary global revenue driver:

FY2024 revenue: ~$2.6B aggregate global (+105% YoY)
FY2025 revenue: ~~$3.0-3.4B aggregate global (~~+30-40% YoY)
Approved indications: chronic lymphocytic leukemia (CLL) + mantle cell lymphoma (MCL) + Waldenström macroglobulinemia (WM) + marginal zone lymphoma (MZL) + selected various B-cell malignancies
US BTK new patient share: ~50%+ aggregate US BTK new patient share FY2025 (selected major competitor Imbruvica/Calquence/Jaypirca)
Geographic mix: US ~75% Brukinsa revenue + EU ~15% + China ~5% + selected various ~5%
Peak sales potential: ~$5-7B+ aggregate

FY2026 catalyst: continued Brukinsa global expansion + ~$0.30-0.50 incremental annual EPS contribution.

Tevimbra (Tislelizumab) Global Launch

Post-2024 Tevimbra global launch represents selected major secondary growth driver:

March 2024 first US FDA approval: esophageal squamous cell carcinoma (ESCC); selected first BeiGene/BeOne Medicines US PD-1 inhibitor approval
Selected post-2024 EU EMA approval expansion: selected various EU markets
FY2025 aggregate global revenue: ~$1.5-2B aggregate global; ~$1B+ China + ~$0.5-1B post-2024 US + EU + selected various
Pipeline: selected ~10+ active Tevimbra global pivotal trials covering selected various lung + gastric + esophageal + selected various indications
Peak sales potential: ~$2-4B+ aggregate

FY2026 catalyst: continued Tevimbra global launch + selected various indication readouts + ~$0.20-0.40 incremental EPS contribution.

BeiGene → BeOne Medicines Rebranding

Post-October 2024 BeiGene → BeOne Medicines rebranding reflects selected major strategic repositioning:

Brand transition: BeiGene → BeOne Medicines + ticker BGNE → ONC (October 2024 effective)
HQ relocation: prior Beijing China → Cambridge Massachusetts US (selected continued China + Switzerland operating sites)
Strategic positioning: selected post-2024 strategic positioning for selected various global expansion + selected post-2024 China oncology pivot
Continued China presence: selected continued post-2024 China commercial + R&D + manufacturing operations

FY2026 catalyst: continued post-October 2024 BeOne Medicines rebranding execution + selected post-2024 China oncology pivot.

Risks

Brukinsa Imbruvica + Calquence + Jaypirca competition: continued BTK inhibitor competitive intensity
Tevimbra PD-1 competitive intensity: Keytruda + Opdivo + selected various PD-1 inhibitor competition
China oncology pivot: continued post-2024 China oncology + selected various execution
R&D pipeline failures: continued ~10+ active pivotal trials execution risk
Currency: USD/CNY + selected various currency volatility

Key Core Metrics

Metric	FY2025	FY2024	FY2023	FY2022	FY2026 outlook
Revenue	$5.3-5.8B	$3.81B	$2.46B	$1.42B	$6.5-7.5B
Brukinsa revenue	$3.0-3.4B	$2.6B	$1.3B	$0.6B	$4.0-4.5B
Tevimbra revenue	$1.5-2B	$0.55B	$0.45B	$0.35B	$2.0-2.5B
Adj. EPS	$1.40-1.85	-$1.10	-$5.65	-$13.65	$2.0-2.6
Adj. operating margin	5-10%	-25%	-50%	-150%+	12-18%

Capital return	FY2025	FY2024	FY2026 outlook
Dividend	None	None	None
Buybacks	None	None	None
Cash + investments	$2.5-3B	$2.5B	$3-3.5B
Capital priority	growth + R&D	growth + R&D	growth + R&D

Market Evaluation

BeOne Medicines trades at selected ~17-22x FY2026 P/E premium vs Vertex Pharmaceuticals (~25-30x) + AbbVie (~13-16x) + Bristol-Myers Squibb (~~10-13x) + Eli Lilly (~~30-40x) reflecting selected continued Brukinsa global franchise leadership (~~$5-7B+ peak sales potential) + selected post-2024 Tevimbra global launch (~~$2-4B+ peak sales potential) + selected post-October 2024 BeOne Medicines rebranding + selected continued ~25-30% China revenue mix. Selected re-rating catalysts include: (1) continued Brukinsa global expansion + ~+30-40% growth; (2) Tevimbra global launch + selected various indication readouts; (3) post-October 2024 BeOne Medicines rebranding execution; (4) FCF positive trajectory inflection; (5) selected continued post-2024 China oncology pivot.

Tevimbra Global Launch Strategic Pivot Deep Dive

BeOne Medicines Tevimbra (tislelizumab; PD-1 inhibitor) global launch represents selected primary strategic pivot vehicle marking selected post-2024 transition from selected post-2010 China-focused biotech to selected post-October 2024 BeOne Medicines global oncology biotech. Tevimbra (originally BGB-A317 from BeiGene early-stage R&D) selected post-March 2024 first US FDA approval for esophageal squamous cell carcinoma (ESCC) creates selected first BeiGene/BeOne Medicines US PD-1 inhibitor approval; selected post-2024 EU EMA approval expansion supports selected various EU markets. Selected ~10+ active Tevimbra global pivotal trials covering selected various lung + gastric + esophageal + selected various indications support selected continued Tevimbra indication expansion FY2025-2027. Selected ~$2-4B+ aggregate peak sales potential supports selected continued FY2026-2030 Tevimbra global franchise growth. Selected post-October 2024 BeiGene → BeOne Medicines rebranding (selected post-2024 strategic positioning + HQ relocation Cambridge Massachusetts US) reflects selected major strategic repositioning supporting selected continued post-2024 China oncology pivot + selected various global expansion. FY2026 catalyst: continued Tevimbra global launch + selected various indication readouts + ~$0.20-0.40 incremental annual EPS contribution.

FY2026 thesis: Brukinsa global franchise leadership + Tevimbra global launch + post-October 2024 BeOne Medicines rebranding + FCF positive trajectory + selected post-2024 China oncology pivot.